Eli Lilly & Co. (NYSE: LLY) has submitted a market approval application to China’s Center for Drug Evaluation (CDE) for Baqsimi, its glucagon nasal powder spray designed to treat severe hypoglycemia in diabetes patients aged four and older.
Drug Details
Hypoglycemia, a common complication during diabetes treatment, can be life-threatening and hinder blood glucose control. Baqsimi offers a convenient emergency solution, administered via nasal mucosa absorption without the need for inhalation. The treatment can be applied within 30 seconds, with a 90% success rate, and carries a lower risk of secondary hyperglycemia compared to traditional glucagon injections.
Clinical Trial Waiver
The National Medical Products Administration (NMPA) granted Eli Lilly a clinical trial waiver for Baqsimi, supported by global and real-world study data, accelerating the drug’s potential market entry in China.-Fineline Info & Tech
